March 2026
Serotonin
What March 2026's 14 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 14 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research on serotonin in March 2026 focused on the mechanisms and therapeutic potential of serotonergic psychedelics, showing consistent evidence that psilocin and related compounds promote neuroplasticity and synaptic strengthening in human neurons and rodent models. Clinical and preclinical studies support rapid and sometimes durable antidepressant effects, though the evidence is limited by small sample sizes, expectancy effects, and blinding challenges. The main caveat is that most findings are from in vitro or animal studies, with human data still preliminary.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Reshaping human neurons. 2026 | experimental study | Supports | Psilocin increases structural complexity and strengthens synaptic connections in human iPSC-derived cortical neurons. | |
| Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders 2026 | review | Supports | Classical serotonergic psychedelics show promise for rapid and durable antidepressant effects, with neurotrophic mechanisms such as BDNF-TrkB signaling contributing to sustained outcomes. | |
| Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. 2026 | in vitro experimental study | Supports | Psilocin, acting through 5-HT2A receptors, increases BDNF abundance, primes neurons for neuroplasticity, enhances neuronal complexity and synaptic protein expression, and increases excitability and synaptic network activity. | |
| Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors 2026 | observational study using existing dataset | Supports | Psilocybin increases propagation speed of infraslow cortical activity, associated with increased functional connectivity and contraction of the principal gradient, potentially mediated by 5HT2a receptor distribution. | |
| Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies 2026 | review | Supports | Recent discoveries of rapid-acting antidepressant effects of ketamine and psychedelic compounds have challenged traditional monoaminergic models and highlighted alternative mechanisms involving glutamatergic signaling, synaptic plasticity, and immune-brain interactions. | |
| Integrated 5-HT 2A –TrkB and G protein signaling in serotonergic psychedelic responses 2026 | in vitro study | Supports | Serotonergic psychedelics recruit an integrated 5-HT2A-TrkB signaling network that drives dendritogenesis, synaptogenesis, gene expression, and lactate production, with ligand-specific differences and dependence on both Gq/11 and Gi/o protein pathways. | |
| Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil. 2026 | cross-sectional survey | 28 | Mixed | Endurance athletes show high openness to psychedelic therapies but also significant knowledge gaps and misconceptions, including widespread belief that psychedelics are addictive. |
| Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials. 2026 | experimental study | Mixed | Chronic fluoxetine treatment reduced the head-twitch response to DOI in male mice, and acute fluoxetine attenuated the efficacy of psilocybin, showing that SSRI history can alter psychedelic effects in a compound-specific way. | |
| Serotonergic modulation of excitatory synapse development and plasticity 2026 | review | Supports | Serotonin signaling through its various receptor subtypes plays a critical role in the development, maturation, and plasticity of excitatory synapses on dendritic spines. | |
| Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response 2026 | preclinical study | Supports | Coadministration of PDE9i with psilocybin reduces psychedelic-like behavior while maintaining antidepressant effects in a mouse model of chronic stress. | |
| Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin 2026 | translational rodent study | Supports | Psilocin modulates negative affective biases by selectively suppressing excitatory input to cortico-amygdala projection neurons in the prelimbic cortex, an effect dependent on 5HT1A and 5HT2A receptor signaling and leading to sustained changes in affective bias. | |
| A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats 2026 | experimental study | Mixed | Repeated low-dose MDMA produced transient mild anxiety-like behavior and reduced serotonin in the nucleus accumbens one day after exposure, with no lasting effects at 15 days. | |
| Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs 2026 | preparative synthesis and in vitro binding assay | Supports | Only psilocin, among psilocybin, psilocin-O-glucuronide, and 4-HIAA, showed discernible binding at seven serotonin receptor subtypes. | |
| Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors 2026 | experimental study | Supports | Psychedelics induce long-lasting synaptic enhancement in the retrosplenial cortex via presynaptic serotonin 2A receptors on anterior thalamic inputs, despite the absence of postsynaptic 5-HT2A receptors. |
Psilocin increases structural complexity and strengthens synaptic connections in human iPSC-derived cortical neurons.
experimental study
Classical serotonergic psychedelics show promise for rapid and durable antidepressant effects, with neurotrophic mechanisms such as BDNF-TrkB signaling contributing to sustained outcomes.
review
Psilocin, acting through 5-HT2A receptors, increases BDNF abundance, primes neurons for neuroplasticity, enhances neuronal complexity and synaptic protein expression, and increases excitability and synaptic network activity.
in vitro experimental study
Psilocybin increases propagation speed of infraslow cortical activity, associated with increased functional connectivity and contraction of the principal gradient, potentially mediated by 5HT2a receptor distribution.
observational study using existing dataset
Recent discoveries of rapid-acting antidepressant effects of ketamine and psychedelic compounds have challenged traditional monoaminergic models and highlighted alternative mechanisms involving glutamatergic signaling, synaptic plasticity, and immune-brain interactions.
review
Serotonergic psychedelics recruit an integrated 5-HT2A-TrkB signaling network that drives dendritogenesis, synaptogenesis, gene expression, and lactate production, with ligand-specific differences and dependence on both Gq/11 and Gi/o protein pathways.
in vitro study
Endurance athletes show high openness to psychedelic therapies but also significant knowledge gaps and misconceptions, including widespread belief that psychedelics are addictive.
cross-sectional survey Sample size: 28
Chronic fluoxetine treatment reduced the head-twitch response to DOI in male mice, and acute fluoxetine attenuated the efficacy of psilocybin, showing that SSRI history can alter psychedelic effects in a compound-specific way.
experimental study
Serotonin signaling through its various receptor subtypes plays a critical role in the development, maturation, and plasticity of excitatory synapses on dendritic spines.
review
Coadministration of PDE9i with psilocybin reduces psychedelic-like behavior while maintaining antidepressant effects in a mouse model of chronic stress.
preclinical study
Psilocin modulates negative affective biases by selectively suppressing excitatory input to cortico-amygdala projection neurons in the prelimbic cortex, an effect dependent on 5HT1A and 5HT2A receptor signaling and leading to sustained changes in affective bias.
translational rodent study
Repeated low-dose MDMA produced transient mild anxiety-like behavior and reduced serotonin in the nucleus accumbens one day after exposure, with no lasting effects at 15 days.
experimental study
Only psilocin, among psilocybin, psilocin-O-glucuronide, and 4-HIAA, showed discernible binding at seven serotonin receptor subtypes.
preparative synthesis and in vitro binding assay
Psychedelics induce long-lasting synaptic enhancement in the retrosplenial cortex via presynaptic serotonin 2A receptors on anterior thalamic inputs, despite the absence of postsynaptic 5-HT2A receptors.
experimental study
Points of agreement
- Psilocin and other serotonergic psychedelics promote neuroplasticity and synaptic strengthening in human and rodent models.
- 5-HT2A receptor signaling is a key mediator of psychedelic-induced plasticity and behavioral effects.
- Psychedelics show rapid and sometimes durable antidepressant effects in clinical and preclinical studies.
- BDNF-TrkB signaling is implicated as a common neurotrophic mechanism underlying sustained therapeutic effects.
Conflicts
- Chronic fluoxetine treatment reduced DOI-induced head-twitch response, while acute fluoxetine attenuated psilocybin efficacy, suggesting compound-specific interactions.
- MDMA produced transient anxiety-like behavior and reduced serotonin in rats, contrasting with the therapeutic benefits of other psychedelics.
- The requirement of 5-HT2A receptors for psychedelic-induced plasticity is debated, as one study shows plasticity in neurons lacking postsynaptic 5-HT2A receptors.
Gaps
- Durability of antidepressant effects beyond short-term follow-up is not established.
- Most evidence comes from in vitro or animal studies; human clinical data are limited.
- Blinding and expectancy effects in clinical trials remain unresolved.
- The role of specific serotonin receptor subtypes beyond 5-HT2A is not fully characterized.
- Effects of chronic SSRI use on psychedelic efficacy in humans are unknown.
- Long-term safety and tolerability of psychedelic treatments are not well studied.